News

The EU is in the decisive stage of a sweeping pharmaceutical law reform aimed at boosting industry competitiveness, improving supply chain resilience, addressing shortages, and accelerating digital transformation.

The US government and Eli Lilly/Novo Nordisk reached a pivotal agreement today to drastically lower GLP-1 drug prices, expand Medicare/Medicaid access, and incentivize new domestic manufacturing projects.

Clariant has completed a CHF 80-million expansion of its Daya Bay, China, facilities, strengthening pharmaceutical excipients and specialty chemicals manufacturing for Asia.

Hikma Pharmaceuticals updates 2025 growth guidance and restructures global R&D to drive manufacturing and pipeline expansion in Europe.

Johnson & Johnson has gained US FDA approval to market Caplyta as a treatment for depression, strengthening its neuropsychiatric portfolio and commercial strategy.

HUTCHMED has completed patient enrollment for its global Phase III trial of ORPATHYS® and TAGRISSO® in advanced NSCLC, advancing a pivotal chemotherapy-free option across Asia-Pacific.

Moberg Pharma and Karo Healthcare finalize a pan-European licensing deal for MOB-015 (Terclara®), targeting coordinated launches and market leadership in antifungal therapy.

Avanos Medical delivered strong Specialty Nutrition Systems growth and closed its acquisition of Nexus Medical, advancing innovation in neonatal and pediatric nutrition despite ongoing tariff pressures.

Global pharma companies set a new record by investing $48.5B in partnerships with Chinese biotechs in the first half of 2025, led by innovations in oncology and next-gen therapeutics.

Eli Lilly announces a $3 billion investment for a new oral medications manufacturing facility in the Netherlands, aiming to expand its European supply chain, create jobs, and deploy next-generation manufacturing technology.